Sep. 10 at 11:39 AM
$DNTH Dianthus Therapeutics stock jumped ~20% to an 18-month high after Phase 2 results for its autoimmune drug claseprubart. RS rating hit 91, the public offering was upsized to ~
$251M, & analysts raised targets (
$100,
$63,
$40, depending on the imagination level). Biotech optimism: a drug works in Phase 2, so the stock behaves like it’s already cured the disease.
#ETSY Etsy’s platform engagement & merchant growth are reinforcing the
$72 level. Consumer-spending resilience (whimsigoth, fetish fashion, handmade crafts, domestic charm).
#SG Sweetgreen’s luxury athleisure lifestyle setting: bright & clean interior, crisp greens, bright wooden textures (post-class vibe) is reinforcing the
$18 level. Where energized femininity resonates.
#XHB Homebuilder demand trends & housing supply dynamics are reinforcing the
$120 level. Fed rate-cut speculation.
#BTC Bitcoin’s on-chain metrics & institutional flows are propping up the
$112,000 level. Fed rate-cut speculation & “liquidity expansion.”
